Abstract
Hyperuricemia is currently recognized as a risk factor for cardiovascular diseases. It has been reported that the angiotensin II-receptor blocker (ARB) losartan decreases serum uric acid level. In this study, the effects of another ARB, irbesartan, on [(14)C]uric acid-transport activity of renal uric acid reabsorptive transporters URAT1 and URATv1 were examined with Xenopus oocytes expressing each transporter. The results showed that irbesartan (100-500 µM) inhibited the uptake of uric acid via both transporters. The inhibitory effects of irbesartan exceeded those of losartan and other ARBs, and the results suggest that irbesartan can reduce serum uric acid level.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biphenyl Compounds / pharmacology*
-
Dose-Response Relationship, Drug
-
Female
-
Irbesartan
-
Kidney / drug effects
-
Kidney / metabolism
-
Organic Anion Transporters / antagonists & inhibitors*
-
Organic Anion Transporters / metabolism*
-
Organic Cation Transport Proteins / antagonists & inhibitors*
-
Organic Cation Transport Proteins / metabolism*
-
Tetrazoles / pharmacology*
-
Uric Acid / antagonists & inhibitors*
-
Uric Acid / metabolism
-
Xenopus
Substances
-
Biphenyl Compounds
-
Organic Anion Transporters
-
Organic Cation Transport Proteins
-
SLC22A12 protein, human
-
Tetrazoles
-
Uric Acid
-
Irbesartan